Part,  Chapter, Paragraph

 1   II,     5.  6.  3|      has been mapped to a short gene sequence now known as the
 2   II,     5. 15.  3|   diseases for which the causal gene(s) is identified and 2,160
 3   II,     5. 15.  4|     EU-wide rules to facilitate gene, cell and tissue-based therapies
 4   II,     8.  2.  1|   syndrome. Identification of a gene for an inherited disorder
 5   II,     9        |    attributed to a known single gene mutation, and under 5% to
 6   II,     9.  1.  2|    attributed to a known single gene mutation, and under 5% to
 7  III,    10.  2.  4|        role of G-308A TNF alpha gene variant in obesity, asthma
 8  III,    10.  2.  4|         conventional microarray gene expression profiling, population-based
 9  III,    10.  2.  4| implemented to quickly validate gene expression microarray data
10  III,    10.  2.  4|       necrosis factor alpha-308 gene promoter and asthma: a meta-analysis.
11  III,    10.  2.  4|     tumor necrosis factor alpha gene variant and phenotypes associated
12  III,    10.  3.  1|        can, when inhaled, cause gene damage, mutations and finally
13   IV,    12. 10    |         and epizootic diseases. Gene therapy as well is closely
14   IV,    12. 10    |       and Committee for Somatic Gene Therapy of the German Medical